Somavert, a new drug for terminal hypertrophy, can be prescribed at a general hospital. According to related industries, Pfizer Korea's Somavert has currently passed DC of the Big 5 higher-level medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, AMC, and Sinchon Severance Hospital.

Currently, it can be prescribed in most major hospitals nationwide. Somavert has been listed on the insurance benefit list since September last year, making it easy to access patients. Somavert demonstrated its validity through a SEN-3614 study, a 12-week randomized, double-blind core study in 12 patients with terminal hypertrophy. 112 patients were randomly ass